HitGen, LEO Pharma partner

Wednesday, August 9, 2017

HitGen announced that the company has entered into a multi-target multi-year collaboration with LEO Pharma to discover novel small molecule leads for multiple therapeutic targets of interest to LEO Pharma. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from LEO Pharma.

[Read More]

HitGen partners with Scripps Research Institute and Calibr

Monday, April 24, 2017

HitGen, a privately held biotech company focused on technology for effective and efficient small molecule drug discovery and development, announced a collaboration with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr). This collaboration is to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.

[Read More]

HitGen, Pfizer collaborate to build and screen novel DNA-encoded libraries

Tuesday, April 18, 2017

HitGen has entered into a multi-year research collaboration and license agreement with Pfizer to build and screen novel DNA-encoded libraries (DELs) in order to potentially discover unique small molecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis and screening of multiple proprietary DELs for Pfizer’s drug discovery efforts.

[Read More]